Natera executive chairman Matthew Rabinowitz sells $20.1m in stock
Matthew Rabinowitz, Executive Chairman of Natera, sold 50,000 shares of the company's stock on October 15, 2026. The sale, worth around $20.1 million, took place pursuant to a pre-authorized trading plan executed on June 12, 2026. The shares were sold at prices ranging from $388.32 to $408.24 per share. Concurrently, Rabinowitz bought 50,000 shares of Natera at $10.41 per share, exercising stock options.
Following these transactions, Rabinowitz now owns 2,119,394 shares of Natera stock. Meanwhile, Natera reported second-quarter revenue surpassing expectations at $753 million, leading to an upward revision of its full-year revenue guidance. This strong performance, coupled with Natera's dominant position in the minimal residual disease (MRD) testing market, has attracted attention from financial analysts.
Despite a Pro Research Report indicating Natera is overvalued, other firms like RBC Capital and Rothschild Redburn have maintained positive outlooks for the company, highlighting its growth prospects in the healthcare sector.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
